Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2000-03-29
2001-05-01
Travers, Russell (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
06225307
ABSTRACT:
TECHNICAL FIELD
This invention relates to certain carbamic acid esters that are effective against viruses and can be used to treat viral infections in animals. The preferred compound is (4-chlorophenyl)-carbamic acid, 3-(hexahydro-3-ethyl- 1-methyl-2-oxo-1H-azepin-3-yl) 2 phenyl ester. The composition can contain one or more of the carbamic acid esters, its pharmaceutical addition salt or prodrugs thereof.
BACKGROUND OF THE INVENTION
HIV and other viral infections, such as hepatitis, are a few of the leading causes of death. HIV is the virus known to cause acquired immunodeficiency syndrome (AIDS) in humans. HIV is a disease in which a virus is replicated in the body or in host cells. The virus attacks the body's immune system.
Several drugs have been approved for treatment of this devastating disease, including azidovudine (AZT), didanosine (dideoxyinosine, ddI), d4T, zalcitabine (dideoxycytosine, ddC), nevirapine, lamivudine (epivir, 3TC), saquinavir (Invirase), ritonavir (Norvir), indinavir (Crixivan), and delavirdine (Rescriptor). See M. I. Johnston & D. F. Hoth,
Science,
260 (5112), 1286-1293 (1993) and D. D. Richman,
Science,
272 (5270), 1886-1888 (1996). An AIDS vaccine (Salk's vaccine) has been tested and several proteins which are chemokines from CD8 have been discovered to act as HIV suppressors. In addition to the above synthetic nucleoside analogs, proteins, and antibodies, several plants and substances derived from plants have been found to have in vitro anti-HIV activity. However, HIV virus is not easily destroyed nor is there a good mechanism for keeping the host cells from replicating the virus.
Thus, medical professionals continue to search for drugs that can prevent HIV infections, treat HIV carriers to prevent their disease from progressing to full-blown deadly AIDS, and to treat the AIDS patient.
Herpes simplex virus (HSV) types 1 and 2 are persistent viruses that commonly infect humans; they cause a variety of troubling human diseases. HSV type 1 causes oral “fever blisters” (recurrent herpes labialis), and HSV type 2 causes genital herpes, which has become a major venereal disease in many parts of the world. No fully satisfactory treatment for genital herpes currently exists. In addition, although it is uncommon, HSV can also cause encephalitis, a life-threatening infection of the brain. (
The Merck Manual,
Holvey, Ed., 1972; Whitley, Herpes Simplex Viruses, In:
Virology,
2nd Ed., Raven Press (1990)). A most serious HSV-caused disorder is dendritic keratitis, an eye infection that produces a branched lesion of the cornea, which can in turn lead to permanent scarring and loss of vision. Ocular infections with HSV are a major cause of blindness. HSV is also a virus which is difficult, if not impossible to cure.
Hepatitis is a disease of the human liver. It is manifested with inflammation of the liver and is usually caused by viral infections and sometimes from toxic agents. Hepatitis may progress to liver cirrhosis, liver cancer, and eventually death. Several viruses such as hepatitis A, B, C, D, E and G are known to cause various types of viral hepatitis. Among them, HBV and HCV are the most serious. HBV is a DNA virus with avirion size of 42 nm. HCV is a RNA virus with a virion size of 30-60 nm. See D. S. Chen,
J. Formos. Med. Assoc.,
95 (1), 6-12 (1996).
Hepatitis C infects 4 to 5 times the number of people infected with HIV. Hepatitis C is difficult to treat and it is estimated that there are 500 million people infected with it worldwide (about 15 time those infected with HIV). No effective immunization is currently available, and hepatitis C can only be controlled by other preventive measures such as improvement in hygiene and sanitary conditions and interrupting the route of transmission. At present, the only acceptable treatment for chronic hepatitis C is interferon which requires at least six (6) months of treatment and or ribavarin which can inhibit viral replication in infected cells and also improve liver function in some people. Treatment with interferon with or without Ribavirin however has limited long term efficacy with a response rate about 25%.
Hepatitis B virus infection lead to a wide spectum of liver injury. Moreover, chronic hepatitis B infection has been linked to the subsequent development of hepatocellular carcinoma, a major cause of death. Current prevention of HBV infection is a hepatitis B vaccination which is safe and effective. However, vaccination is not effective in treating those already infected (i.e., carriers and patients). Many drugs have been used in treating chronic hepatitis B and none have been proven to be effective, except interferon.
Treatment of HCV and HBV with interferon has limited success and has frequently been associated with adverse side effects such as fatigue, fever, chills, headache, myalgias, arthralgias, mild alopecia, psychiatric effects and associated disorders, autoimmune phenomena and associated disorders and thyroid dysfunction.
Because the interferon therapy has limited efficacy and frequent adverse effects, a more effective regimen is needed.
In the present invention it has been discovered that the compounds described above are useful for the treatment of hepatitis C virus, hepatitis B virus, herpes simplex and the treatment of HIV infection and other viral infections.
SUMMARY OF THE INVENTION
A pharmaceutical composition for treatment of animals, and in particular, warm blooded animals, including humans, comprising a pharmaceutical carrier and an effective amount of an aryl carbamic acid ester having the following formula:
wherein X is independently oxygen or sulfur, R is selected from the group consisting of hydrogen and alkyl having from 1 to 4 carbon atoms, R
1
is selected from the group consisting of hydrogen and alkyl having from 1 to 4 carbon atoms, wherein R
2
is independently selected from the group consisting of hydrogen and alkyl having from 1 to 4 carbon atoms, and wherein Y is selected from the group consisting of hydrogen, chloro, fluoro, bromo, hydroxy and sulfhydryl or a pharmaceutical addition salts or prodrug thereof.
The preferred compound is (4-chlorophenyl)-carbamic acid, 3-(hexahydro-3-ethyl-1-methyl-2-oxo-1H-azepin-3-yl) 2 phenyl ester; wherein X is oxygen, Y is chloro, R is hydrogen, R
2
is ethyl and R
1
is methyl.
The compositions can be used in a method of treating HIV, in particular chronic HIV, and other viral infections. The drug can be given daily in one or more doses and from 1 to 4 times a week.
The compositions can be used in conjunction with other treatments for the viral infections.
DETAILED DESCRIPTION OF THE INVENTION
A. Definitions:
As used herein “alkyl” includes straight, branched chain and cyclic alkanes.
As used herein “aryl” includes phenyl or phenyl derivatives, for example, chlorophenyl, fluorophenyl, or methylphenyl.
As used herein, the term “safe and effective amount” refers to the quantity of a component which is sufficient to yield a desired therapeutic response without undue adverse side effects (such as toxicity, irritation, or allergic response) commensurate with a reasonable benefit/risk ratio when used in the manner of this invention.
As used herein, the term “therapeutically effective amount” is meant an amount of a compound of the present invention effective to yield the desired therapeutic response. For example to inhibit HIV infection or treat the symptoms of infection in a host or an amount effective to treat hepatitis. The specific safe and effective amount or therapeutically effective amount will, obviously, vary with such factors as the particular condition being treated, the physical condition of the patient, the type of mammal being treated, the duration of the treatment, the nature of concurrent therapy (if any), and the specific formulations employed and the structure of the compounds or its derivatives.
As used herein, a “pharmaceutical addition salts” is salt of the aryl carbamic acid ester derivative which is modified by making acid or base salts of the compound. Examples of pharmaceutically acceptable
Camden James Berger
Gardner Joseph Herman
Stanton David Thomas
Dabek Rose Ann
Miller Steven W.
The Procter & Gamble & Company
Travers Russell
LandOfFree
Viral treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Viral treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Viral treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2466115